EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neuromyelitis optica spectrum disorder in Germany: A claims data analysis of incidence, prevalence, treatment patterns, and diagnostic overlap with multiple sclerosis

Matthias Grothe iD, Katja Nettermann, Ursula Marschall, Klaus Berger

Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-04 · 12 (2)

DOI: 10.1177/20552173261419988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 07.05.2026. Verfasst von Matthias Grothe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Medicine Greifswald, Germany. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuromyelitis optica spectrum disorders (NMOSD) are rare autoimmune diseases of the central nervous system. Global prevalence estimates vary widely, and data for Germany are limited.

Objectives

To estimate NMOSD prevalence, incidence, diagnostic settings, comorbid coding with multiple sclerosis (MS), and treatment patterns in Germany.

Methods

We analyzed German BARMER health insurance claims data (approximately 9 million persons; 2015–2022). NMOSD cases were identified by ICD-10-GM code G36.0. Frequencies, diagnostic settings, comorbid MS coding (G35.-), and treatment patterns (Anatomical Therapeutic Chemical codes) were assessed.

Results

We identified 527 incident NMOSD cases (0.82 per 100,000 insured persons per year); 69% were female, and 42% aged 40–59 years. Most diagnoses occurred in outpatient care (63%), primarily by neurologists (48%) or general practitioners (28%). Prevalence increased from 2.9 to 4.7 per 100,000 between 2015 and 2022, while NMOSD-specific medication use rose from 16% to 31%. NMOSD and MS codes co-occurred in 64% of cases; 49% had concurrent diagnoses within 9 months, and 42% were first diagnosed with MS.

Conclusion

NMOSD prevalence and incidence in Germany are increasing, with frequent diagnostic overlap with MS. Findings highlight the need for improved diagnostic differentiation and early specialist involvement.

Schlagwörter

Stichwörter der Autor:innen

NMOSDepidemiologyincidenceprevalence

Autor:innen und Institutionen

  • Department of Neurology, University Medicine Greifswald, Germany.
  • Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
  • Department of Medicine and Health Services Research at Barmer, Wuppertal, Germany.
  • is currently affiliated with University of Greifswald.

ORCID-Profile: Matthias Grothe

Zitieren

APA

Grothe, M., Nettermann, K., Marschall, U., & Berger, K. (2026). Neuromyelitis optica spectrum disorder in Germany: A claims data analysis of incidence, prevalence, treatment patterns, and diagnostic overlap with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(2). https://doi.org/10.1177/20552173261419988

Vancouver

Grothe M, Nettermann K, Marschall U, Berger K. Neuromyelitis optica spectrum disorder in Germany: A claims data analysis of incidence, prevalence, treatment patterns, and diagnostic overlap with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(2). doi:10.1177/20552173261419988

BibTeX
@article{Grothe2026,
  author = {Grothe, Matthias and Nettermann, Katja and Marschall, Ursula and Berger, Klaus},
  title = {Neuromyelitis optica spectrum disorder in Germany: A claims data analysis of incidence, prevalence, treatment patterns, and diagnostic overlap with multiple sclerosis},
  journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1177/20552173261419988}
}
Kostenlos starten →